Phase 1 data of mdc-TJK investigational long-acting injectable of olanzapine for schizophrenia patients, exhibited favorable characteristics of an extended-release profile
May 22, 2023
May 22, 2023
MedinCell announces the successful pricing of its Global Offering and raises €25 million
May 12, 2023
May 12, 2023
MedinCell launches a Global Offering for approximately 25 million euros
May 11, 2023
May 11, 2023
MedinCell: mdc-TJK’s (Teva’s codename: TEV-44749) Phase 1 study pharmacokinetics to be presented for the first time by Teva at SIRS 2023 (May 11-15, 2023, Toronto, Canada)
May 4, 2023
May 4, 2023
First FDA approval and US commercial launch, MedinCell enters new era
May 2, 2023
May 2, 2023
Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults
April 28, 2023
April 28, 2023
MedinCell: SAIVE Study data to be presented at ECCMID 2023 Euronext: MEDCL
April 17, 2023
April 17, 2023
MedinCell announces the initiation of coverage of its stock by Portzamparc – BNP Paribas Group
March 27, 2023
March 27, 2023
MedinCell receives “Prime” ISS ESG rating as a recognition of the embedment of Corporate Social Responsibility across the Company
February 23, 2023
February 23, 2023
Contacts
Medincell
David Heuzé
Head of Corporate and Financial Communications, and ESG
